2019 / 06

Next Paper
DOI: 10.24075/brsmu.2019.075

ORIGINAL RESEARCH

Hepatoprotective effect of polyphenols in rats with experimental thioacetamide-induced toxic liver pathology

Dergachova DI1, Klein OI1, Marinichev AA1,2, Gessler NN1, Bogdanova ES3, Smirnova MS3, Isakova EP1, Deryabina YI1
About authors

1 Bach Institute of Biochemistry, Federal Research Centre “Fundamentals of Biotechnology” RAS, Moscow, Russia

2 Mendeleyev University of Chemical Technology of Russia, Moscow

3 Vavilov Institute of General Genetics, Moscow, Russia

Correspondence should be addressed: Maria S. Smirnova
Moskvina, 10–226, Khimki, Moscow Region, 141401; ur.ay@oktobrabm

About paper

Funding: the study was supported by the Ministry of Education and Science of the Russian Federation (agreement № 14.616.21.0083, unique project ID: RFMEFI61617X0083).

Acknowledgement: we thank to the Center for Precision Genome Editing and Genetic Technologies for Biomedicine (Moscow) for the genetic research methods.

Author contribution: Dergachova DI — conducting experiments on toxic hepatitis induction, histological analysis, manuscript draft preparation; Klein OI — histological studies, data acquisition and analysis; Marinichev AA — experiments on toxic hepatitis induction, blood sample collection from experimental animals, preparation of histological samples; Gessler NN — conducting experiments on toxic hepatitis induction, blood sample collection from experimental animals, data acquisition and analysis; Bogdanova ES, Smirnova MS — literature analysis, data acquisition and analysis; Isakova EP — conducting experiments on toxic hepatitis induction, literature analysis; Deryabina YI — experiment planning, literature analysis, data acquisition and analysis.

Received: 2019-10-26 Accepted: 2019-11-17 Published online: 2019-11-28
|
  1. Li S, Tan HY, Wang N, Cheung F, Hong M, Feng Y. The potential and action mechanism of polyphenols in the treatment of liver diseases. Oxid Med Cell Longev. 2018; 8394818. DOI: 10.1155/2018/8394818.
  2. Raff E, Singal AK. Optimal management of alcoholic hepatitis. Minerva Gastroenterol Dietol. 2014; 60 (1): 25–38.
  3. Riggio O, Ridola L, Pasquale C. World J Gastrointest Pharmacol Ther Hepatic encephalopathy therapy: An overview. 2010; 1 (2): 54–63.
  4. Neuschwander-Tetri BA. Non-alcoholic fatty liver disease. BMC Med. 2017; 15 (1): 45.
  5. Popov VB, Lim JK. Treatment of nonalcoholic fatty liver disease: The role of medical, surgical, and endoscopic weight loss. J Clin Transl Hepatol. 2015; 3 (3): 230–38.
  6. Hong M, Li S, Tan H, Wang N, Tsao SW, Feng Y. Current status of herbal medicines in chronic liver disease therapy: the biological effects, molecular targets and future prospects. Int J Mol Sci. 2015; 16 (12): 28705–45.
  7. Festi D, Vestito A, Mazzella G, Roda E, Colecchia A. Management of hepatic encephalopathy: focus on antibiotic therapy. Digestion. 2006; 73 (Suppl. 1): 94–101.
  8. Malaguarnera M, Gargante MP, Malaguarnera G, Salmeri M, Mastrojeni S, Rampello L, et al. Bifidobacterium combined with fructo-oligosaccharide versus lactulose in the treatment of patients with hepatic encephalopathy. Eur J Gastroenterol Hepatol. 2010; 22 (2): 199–206.
  9. Efrati C, Masini A, Merli M, Valeriano V, Riggio O. Effect of sodium benzoate on blood ammonia response to oral glutamine challenge in cirrhotic patients: a note of caution. Am J Gastroenterol. 2000; 95 (12): 3574–78.
  10. Plauth M, Cabre E, Riggio O, Assis-Camilo M, Pirlich M, Kondrup J, et. al. ESPEN guidelines on enteral nutrition: liver disease. Clin Nutr. 2006; 25 (2): 285–94.
  11. Wong VW, Singal AK. Emerging medical therapies for non-alcoholic fatty liver disease and for alcoholic hepatitis. Transl Gastroenterol Hepatol. 2019; (4): 53.
  12. Minushkin ОN, Maslovsky LV, Bukshuk АА. The use of hepatic protectors in clinical practice. Zh Nevrol Psikhiatr Im SS Korsakova. 2012; 10 (2): 67–72.
  13. Teplova VV, Isakova EP, Klein OI, Dergacheva DI, Gessler NN, Deryabina YI. Natural Polyphenols: Biological Activity, Pharmacological Potential, Means of Metabolic Engineering (Review). Applied Biochemistry and Microbiology. 2018; 54 (3): 221–37.
  14. Quideau S, Deffieux D, Douat-Casassus C, Pouysegu L. Plant polyphenols: chemical properties, biological activities, and synthesis. Angewandte Chemie Intern Edition. 2011; 50 (3): 586–621.
  15. Ma JQ, Li Z, Xie WR, Liu CM, Liu SS. Quercetin protects mouse liver against CCl4-induced inflammation by the TLR2/4 and MAPK/NF-κB pathway. Intern Immunopharm. 2014; 28 (1): 531–39.
  16. Ma JQ, Ding J, Zhao H, Liu CM. Puerarin attenuates carbon tetrachloride-induced liver oxidative stress and hyperlipidaemia in mouse by JNK/c-Jun/CYP7A1 pathway. Basic Clin Pharmacol Toxicol. 2014; 115 (5): 389–95.
  17. Liao CC, Day YJ, Lee HC, Liou JT, Chou AH, Liu FC. ERK signaling pathway plays a key role in baicalin protection against acetaminophen-induced liver injury. Am J Chinese Med. 2017; 45 (1): 105–21.
  18. Wallace MC, Hamesch K, Lunova M, Kim Y, Weiskirchen R, Strnad P, et. al. Standard operating procedures in experimental liver research: thioacetamide model in mice and rats. Laboratory Animals. 2015; 49 (S1): 21–9.
  19. Xie Y, Wang G, Wang H, Yao X, Jiang S, Kang A, et. al. Cytochrome P450 dysregulations in thioacetamide-induced liver cirrhosis in rats and the counteracting effects of hepatoprotective agents. Drug Metabolism and Disposition. 2012; 40 (4): 796–802.
  20. Ingawale DK, Mandlik SK, Naik SR. Models of hepatotoxicity and the underlying cellular, biochemical and immunological mechanism(s): a critical discussion. Environ Toxicol Pharmacol. 2014; 37 (1): 118–33.
  21. Seif El-Din SH, El-Lakkany NM, Salem MB, Hammam OA, Saleh S, Botros SS. Resveratrol mitigates hepatic injury in rats by regulating oxidative stress, nuclear factorkappa B, and apoptosis. J Advanc Pharmaceut Technol Res. 2016; 7 (3): 99–104.
  22. Frank GA, Malkov PG, редакторы. 101 shag na puti k uspekhu v gistologii. Leica Microsystems Vetzlar, Germany; 2012. 136 с. Russisn.
  23. Kang MC, Kang SM, Ahn G, Kim KN, Kang N, Samarakoon KW, et. al. Protective effect of a marine polyphenol, dieckol against carbon tetrachlorideinduced acute liver damage in mouse. Environ Toxicol Pharmacol. 2013; 35 (3): 517–23.
  24. Kang MC, Kang SM, Ahn G, Kim KN, Kang N, Samarakoon KW, et. al. Protective effect of a marine polyphenol, dieckol against carbon tetrachlorideinduced acute liver damage in mouse. Environ Toxicol Pharmacol. 2013; 35 (3): 517–23.
  25. Kim DW, Cho HI, Kim KM, Kim YS. Isorhamnetin-3-O-galactoside protects against CCl4-induced hepatic injury in mice Biomolecules Therapeutics. 2012; 20 (4): 406–12.
  26. Huang X, Lian T, Guan X., Liu B, Hao S, Zhang J, et. al. Dihydromyricetin reduces TGF-β via P53 activation-dependent mechanism in hepatocellular carcinoma HepG2 cells. Protein Pept Lett. 2017; 24 (5): 419–24.
  27. Zheng L, Yin L, Xu L, Qi Y, Li H, Xu Y, et. al. Protective effect of dioscin against thioacetamide-induced acute liver injury via FXR/ AMPK signaling pathway in vivo. Biomed Pharmacother. 2018; (97): 481–8. DOI: 10.1016/j.biopha.2017.10.153.